Evidence map›Paper›PMID 27172220›Full record

ArticleG3 (Bethesda, Md.)2016

Copy Number Profiling of Brazilian Astrocytomas.

Lucas Tadeu Bidinotto, Raul Torrieri, Alan Mackay, Gisele Caravina Almeida, Marta Viana-Pereira, Adriana Cruvinel-Carloni, Maria Luisa Spina, Nathalia Cristina Campanella, Weder Pereira de Menezes, Carlos Afonso Clara and 3 more

Open access · goldAbstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Regulation of the Blood-Brain Barrier in Health and Disease.Cold Spring Harbor perspectives in medicine · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Detection and Correlation of Single and ConcomitantInternational journal of molecular sciences · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Lucas Tadeu BidinottoMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, São Paulo, 14785 002, Brazil.
Raul TorrieriMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Alan MackayDivision of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG, UK Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Gisele Caravina AlmeidaDepartment of Pathology, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Marta Viana-PereiraLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, 4704 553, Portugal 3B's - PT Government Associate Laboratory, Braga/Guimarães, 4704 553, Portugal.
Adriana Cruvinel-CarloniMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Maria Luisa SpinaMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, São Paulo, 14785 002, Brazil.
Nathalia Cristina CampanellaMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Weder Pereira de MenezesMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Carlos Afonso ClaraDepartment of Neurosurgery, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Aline Paixão BeckerMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil.
Chris JonesDivision of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG, UK Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Rui Manuel ReisMolecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, 14784 400, Brazil Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, 4704 553, Portugal 3B's - PT Government Associate Laboratory, Braga/Guimarães, 4704 553, Portugal ruireis.hcb@gmail.com.
Hospital São Paulo · BRHospital de Câncer de Barretos · BRInstitute of Cancer Research · GBUniversity of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copy number alterations (CNA) are one of the driving mechanisms of glioma tumorigenesis, and are currently used as important biomarkers in the routine setting. Therefore, we performed CNA profiling of 65 astrocytomas of distinct malignant grades (WHO grade I-IV) of Brazilian origin, using array-CGH and microsatellite instability analysis (MSI), and investigated their correlation with TERT and IDH1 mutational status and clinico-pathological features. Furthermore, in silico analysis using the Oncomine database was performed to validate our findings and extend the findings to gene expression level. We found that the number of genomic alterations increases in accordance with glioma grade. In glioblastomas (GBM), the most common alterations were gene amplifications (PDGFRA, KIT, KDR, EGFR, and MET) and deletions (CDKN2A and PTEN) Log-rank analysis correlated EGFR amplification and/or chr7 gain with better survival of the patients. MSI was observed in 11% of GBMs. A total of 69% of GBMs presented TERT mutation, whereas IDH1 mutation was most frequent in diffuse (85.7%) and anaplastic (100%) astrocytomas. The combination of 1p19q deletion and TERT and IDH1 mutational status separated tumor groups that showed distinct age of diagnosis and outcome. In silico validation pointed to less explored genes that may be worthy of future investigation, such as CDK2, DMRTA1, and MTAP Herein, using an extensive integrated analysis, we indicated potentially important genes, not extensively studied in gliomas, that could be further explored to assess their biological and clinical impact in astrocytomas.

Indexed as

Gene DosageGene Expression Regulation, NeoplasticAdolescentAdultAgedAstrocytomaBrain NeoplasmsBrazilChildComparative Genomic HybridizationCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18ErbB ReceptorsFemaleGlioblastomaHumansCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18EGFR protein, humanErbB ReceptorsIDH1 protein, humanIsocitrate DehydrogenaseKDR protein, humanMET protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-kitProto-Oncogene Proteins c-metPTEN PhosphohydrolasePTEN protein, humanReceptor, Platelet-Derived Growth Factor alphaTelomeraseTERT protein, humanVascular Endothelial Growth Factor Receptor-2genomicsglioblastomasgliomasIDH1TERT

Identifiers

PMID27172220
PMCPMC4938641
OpenAlexW2463923581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.